What the FDA labels say about taking them together
Potassium chloride and triamterene
Potassium chloride's FDA label of July 14, 2025 names triamterene in its contraindications section; triamterene's label does not name potassium chloride itself but warns about its class (potassium salts). The potassium chloride label: “DRUG INTERACTIONS Triamterene and amiloride: Concomitant use is contraindicated Renin-angiotensin-aldosterone inhibitors:”
Check it at the source: the potassium chloride FDA label on DailyMed (effective July 14, 2025, Upsher-Smith Laboratories, LLC); the triamterene FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.).
What does the potassium chloride label say about triamterene?
Potassium chloride label, contraindicationsHyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) [see OVERDOSAGE ].
Potassium chloride label, warningsInteraction with Potassium-Sparing Diuretics Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.
Klor-Con label (Upsher-Smith Laboratories, LLC, July 14, 2025), contraindicationsCONTRAINDICATIONS Potassium chloride is contraindicated in patients on triamterene and amiloride. Concomitant use with triamterene and amiloride
Klor-Con label (Upsher-Smith Laboratories, LLC, July 14, 2025), drug interactionsDRUG INTERACTIONS Triamterene and amiloride: Concomitant use is contraindicated ( 7.1 ) Renin-angiotensin-aldosterone inhibitors:
Source: FDA drug label (Klor-Con, NDA019123), Upsher-Smith Laboratories, LLC, effective July 14, 2025 (SPL set 1ff53330-065c-4213-9c0c-ac498621d09d), via openFDA
Source: FDA drug label (KLOR-CON M), Upsher-Smith Laboratories, LLC, effective July 14, 2025 (SPL set b89910f6-4ff5-4a62-8269-696f7c10e4f6), via openFDA; the full label on DailyMed
What does the triamterene label say about potassium chloride?
Triamterene's label does not name potassium chloride itself; it warns about its class (potassium salts):
Triamterene label, contraindicationsPatients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with Dyrenium.
Triamterene label, drug interactionsThe following agents, given together with triamterene, may promote serum potassium accumulation and possibly result in hyperkalemia because of the potassium-sparing nature of triamterene, especially in patients with renal insufficiency: blood from blood bank (may contain up to 30 mEq of potassium per liter of plasma or up to 65 mEq per liter of whole blood when stored for more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per liter); …
Source: FDA drug label (Dyrenium), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set ebb177c0-d45d-4443-a85a-e76bd9931a42), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Potassium chloride | Triamterene | |
|---|---|---|
| Labeled for | n/a | Heart failure, Edema (fluid retention) |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0828 per tablet 10 mEq tablet | $5.98 per capsule 50 mg capsule |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once